West Syndrome Is an Exceptional Presentation of Pyridoxine- and Pyridoxal Phosphate-Dependent Epilepsy: Data From a French Cohort and Review of the Literature

Marc Gibaud, Magalie Barth, Jérémie Lefranc, Karine Mention, Nathalie Villeneuve, Manuel Schiff, Hélène Maurey, Marie-Anne Barthez, Isabelle Caubel, Mondher Chouchane, Diane Doummar, Manoëlle Kossorotoff, Marie-Dominique Lamblin, Agathe Roubertie, Rima Nabbout, Patrick Van Bogaert, Marc Gibaud, Magalie Barth, Jérémie Lefranc, Karine Mention, Nathalie Villeneuve, Manuel Schiff, Hélène Maurey, Marie-Anne Barthez, Isabelle Caubel, Mondher Chouchane, Diane Doummar, Manoëlle Kossorotoff, Marie-Dominique Lamblin, Agathe Roubertie, Rima Nabbout, Patrick Van Bogaert

Abstract

Objective: To characterize the electro-clinical presentation of patients with pyridoxine-dependent epilepsy (PDE) and pyridoxal phosphate (PLP)-dependent epilepsy in order to determine whether some of them could be diagnosed as de novo West syndrome, i. e., West syndrome that starts after the age of 2 months without other types of seizures (focal seizures for instance) before the onset of epileptic spasms. Methods: We analyzed data from an unpublished cohort of 28 genetically confirmed cases of PDE with antiquitine (ATQ) deficiency and performed a review of the literature looking for description of West syndrome in patients with either PDE with ATQ deficiency or PLP-dependent epilepsy with Pyridox(am)ine phosphate oxidase (PNPO) deficiency. Results: Of the 28 cases from the ATQ deficiency French cohort, 5 had spasms. In four cases, spasms were associated with other types of seizures (myoclonus, focal seizures). In the last case, seizures started on the day of birth. None of these cases corresponded to de novo West syndrome. The review of the literature found only one case of PNPO deficiency presenting as de novo West syndrome and no case of ATQ deficiency. Significance: The presentation of PDE- and PLP-dependent epilepsy as de novo West syndrome is so exceptional that it probably does not justify a systematic trial of pyridoxine or PLP. We propose considering a therapeutic trial with these vitamins in West syndrome if spasms are associated with other seizure types or start before the age of 2 months.

Keywords: B6; West syndrome; antiquitine; epilepsy; infantile; pyridoxal phosphate; pyridoxine; spasms.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Gibaud, Barth, Lefranc, Mention, Villeneuve, Schiff, Maurey, Barthez, Caubel, Chouchane, Doummar, Kossorotoff, Lamblin, Roubertie, Nabbout and Van Bogaert.

References

    1. Trevathan E, Murphy CC, Yeargin-Allsopp M. The descriptive epidemiology of infantile spasms among atlanta children. Epilepsia. (1999) 40:748–51. 10.1111/j.1528-1157.1999.tb00773.x
    1. Hrachovy RA, Frost JD. Infantile spasms. Handb Clin Neurol. (2013) 111:611–8. 10.1016/B978-0-444-52891-9.00063-4
    1. Salar S, Moshé SL, Galanopoulou AS. Metabolic etiologies in West syndrome. Epilepsia Open. (2018) 3:134–66. 10.1002/epi4.12102
    1. Alrifai MT, AlShaya MA, Abulaban A, Alfadhel M. Hereditary neurometabolic causes of infantile spasms in 80 children presenting to a tertiary care center. Pediatr Neurol. (2014) 51:390–7. 10.1016/j.pediatrneurol.2014.05.015
    1. Wilson MP, Plecko B, Mills PB, Clayton PT. Disorders affecting vitamin B 6 metabolism. J Inherit Metab Dis. (2019) 42:629–46. 10.1002/jimd.12060
    1. Coughlin CR II, van Karnebeek CDM, Al-Hertani W, Shuen AY, Jaggumantri S, Jack RM, et al. . Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: neurodevelopmental outcome. Mol Genet Metab. (2015) 116:35–43. 10.1016/j.ymgme.2015.05.011
    1. Darin N, Reid E, Prunetti L, Samuelsson L, Husain RA, Wilson M, et al. . Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B 6 -dependent epilepsy. Am J Hum Genet. (2016) 99:1325–37. 10.1016/j.ajhg.2016.10.011
    1. Struys EA, Nota B, Bakkali A, Al Shahwan S, Salomons GS, Tabarki B. Pyridoxine-dependent epilepsy with elevated urinary α-amino adipic semialdehyde in molybdenum cofactor deficiency. Pediatrics. (2012) 130:e1716-1719. 10.1542/peds.2012-1094
    1. Plecko B, Paul K, Mills P, Clayton P, Paschke E, Maier O, et al. . Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology. (2014) 82:1425–33. 10.1212/WNL.0000000000000344
    1. Mills PB, Camuzeaux SSM, Footitt EJ, Mills KA, Gissen P, Fisher L, et al. . Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain J. Neurol. (2014) 137(Pt 5):1350–60. 10.1093/brain/awu051
    1. Pearl PL, Hyland K, Chiles J, McGavin CL, Yu Y, Taylor D. Partial pyridoxine responsiveness in PNPO deficiency. JIMD Rep. (2013) 9:139–42. 10.1007/8904_2012_194
    1. Bok LA, Halbertsma FJ, Houterman S, Wevers RA, Vreeswijk C, Jakobs C, et al. . Long-term outcome in pyridoxine-dependent epilepsy: long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol. (2012) 54:849–54. 10.1111/j.1469-8749.2012.04347.x
    1. van Karnebeek CDM, Tiebout SA, Niermeijer J, Poll-The BT, Ghani A, Coughlin CR, II, et al. . Pyridoxine-dependent epilepsy: an expanding clinical spectrum. Pediatr Neurol. (2016) 59:6–12. 10.1016/j.pediatrneurol.2015.12.013
    1. Nabbout R, Soufflet C, Plouin P, Dulac O. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed. (1999) 81:F125–9. 10.1136/fn.81.2.F125
    1. Mills PB, Footitt EJ, Mills KA, Tuschl K, Aylett S, Varadkar S, et al. . Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain. (2010) 133:2148–59. 10.1093/brain/awq143
    1. O'Callaghan FJK, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, et al. . Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. (2017) 16:33–42. 10.1016/S1474-4422(16)30294-0
    1. Riikonen R. ACTH therapy of West syndrome: finnish views. Brain Dev. (2001) 23:642–6. 10.1016/S0387-7604(01)00306-0
    1. Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S, et al. . Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia. (2004) 45:255–62. 10.1111/j.0013-9580.2004.30503.x
    1. O'Callaghan FJK, Edwards SW, Alber FD, Borja MC, Hancock E, Johnson AL, et al. . Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. (2018) 2:715–25. 10.1016/S2352-4642(18)30244-X
    1. O'Callaghan FJK, Lux AL, Darke K, Edwards SW, Hancock E, Johnson AL, et al. . The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study: Lead Time and Age in Infantile Spasms. Epilepsia. (2011) 52:1359–64. 10.1111/j.1528-1167.2011.03127.x
    1. Basura GJ, Hagland SP, Wiltse AM, Gospe SM. Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry. Eur J Pediatr. (2008) 168:697–704. 10.1007/s00431-008-0823-x
    1. Coughlin CR, Tseng LA, Abdenur JE, Ashmore C, Boemer F, Bok LA, et al. . Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. (2021) 44:178–92. 10.1002/jimd.12332
    1. Knupp KG, Leister E, Coryell J, Nickels KC, Ryan N, Juarez-Colunga E, et al. . Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia. (2016) 57:1834–42. 10.1111/epi.13557
    1. Ohtahara S, Yamatogi Y. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy. Epilepsy Res. (2006) 70:58–67. 10.1016/j.eplepsyres.2005.11.021
    1. Bennett CL, Chen Y, Hahn S, Glass IA, Gospe SM. Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients. Epilepsia. (2009) 50:1167–75. 10.1111/j.1528-1167.2008.01816.x
    1. Battaglioli G, Rosen DR, Gospe SM, Martin DL. Glutamate decarboxylase is not genetically linked to pyridoxine-dependent seizures. Neurology. (2000) 55:309–11. 10.1212/WNL.55.2.309
    1. Bennett CL, Huynh HM, Chance PF, Glass IA, Gospe SM. Genetic heterogeneity for autosomal recessive pyridoxine-dependent seizures. Neurogenetics. (2005) 6:143–9. 10.1007/s10048-005-0221-8
    1. Mefford HC, Zemel M, Geraghty E, Cook J, Clayton PT, Paul K, et al. . Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination. Neurology. (2015) 85:756–62. 10.1212/WNL.0000000000001883
    1. Mills PB. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum Mol Genet. (2005) 14:1077–86. 10.1093/hmg/ddi120
    1. Liu X-M, Li R, Chen S-Z, Sang Y, Chen J, Fan C-H, et al. . Screening of inherited metabolic disorders in infants with infantile Spasms. Cell Biochem Biophys. (2015) 72:61–5. 10.1007/s12013-014-0404-8
    1. Xue J, Qian P, Li H, Wu Y, Xiong H, Zhang Y-H, et al. . Clinical characteristics of two cohorts of infantile spasms: response to pyridoxine or topiramate monotherapy. World J Pediatr WJP. (2018) 14:290–7. 10.1007/s12519-018-0127-9
    1. Michaud JL, Lachance M, Hamdan FF, Carmant L, Lortie A, Diadori P, et al. . The genetic landscape of infantile spasms. Hum. Mol. Genet. (2014) 23:4846–58. 10.1093/hmg/ddu199
    1. Yamamoto H, Sasamoto Y, Miyamoto Y, Murakami H, Kamiyama N. A successful treatment with pyridoxal phosphate for West syndrome in hypophosphatasia. Pediatr Neurol. (2004) 30:216–8. 10.1016/j.pediatrneurol.2003.08.003
    1. Ohtsuka Y, Matsuda M, Ogino T, Kobayashi K, Ohtahara S. Treatment of the West syndrome with high-dose pyridoxal phosphate. Brain Dev. (1987) 9:418–21. 10.1016/S0387-7604(87)80116-X
    1. Pietz J, Benninger C, Schäfer H, Sontheimer D, Mittermaier G, Rating D. Treatment of infantile spasms with high-dosage vitamin B6. Epilepsia. (1993) 34:757–63. 10.1111/j.1528-1157.1993.tb00458.x
    1. Debus OM, Kurlemann G, Study group . Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia. (2004) 45:103–8. 10.1111/j.0013-9580.2004.19003.x
    1. Heiskala H, Riikonen R, Santavuori P, Simell O, Airaksinen E, Nuutila A, et al. . West syndrome: individualized ACTH therapy. Brain Dev. (1996) 18:456–60. 10.1016/S0387-7604(96)00024-1
    1. Kunnanayaka V, Jain P, Sharma S, Seth A, Aneja S. Addition of pyridoxine to prednisolone in the treatment of infantile spasms: a pilot, randomized controlled trial. Neurol India. (2018) 66:385–90. 10.4103/0028-3886.227281
    1. Kaushik JS, Patra B, Sharma S, Yadav D, Aneja S. Clinical spectrum and treatment outcome of West Syndrome in children from Northern India. Seizure. (2013) 22:617–21. 10.1016/j.seizure.2013.04.014
    1. Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, Ashwal S, et al. . Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. (2012) 78:1974–80. 10.1212/WNL.0b013e318259e2cf

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever